4.7 Review

How to Diagnose and Treat Local Allergic Rhinitis: A Challenge for Clinicians

Journal

JOURNAL OF CLINICAL MEDICINE
Volume 8, Issue 7, Pages -

Publisher

MDPI
DOI: 10.3390/jcm8071062

Keywords

local allergic rhinitis; nasal allergen challenge; allergen immunotherapy

Funding

  1. Instituto de Salud Carlos III of the Spanish Ministry of Science, Innovation and Universities - European Regional Development Fund [PI17/01410]
  2. Network for Collaborative Research on Allergy and Asthma-ARADyAL [RD16/0006/0001]
  3. [CM17/00140]
  4. [CM17/00141]
  5. [JR18/00054]

Ask authors/readers for more resources

Chronic rhinitis is a very common disease that can be divided in various phenotypes. Historically, the condition has been classified into the allergic rhinitis (AR) and non-allergic non-infectious rhinitis (NAR) forms, based on the results of the classical biomarkers of atopy: skin prick test and serum allergen-specific IgE However, this classification does not reflect the complexity of the rhinitis syndrome, as illustrated by the existence of non-atopic rhinitis patients who display a nasal reactivity to environmental allergens. This new phenotype has been termed local allergic rhinitis (LAR) and can be only recognized if an additional test such as the nasal allergen challenge (NAC) is integrated in the diagnostic algorithm for chronic rhinitis. Recent data shows that the NAC is a very safe and reliable technique ready for the clinical practice. LAR is a differentiated rhinitis phenotype which often commences during childhood and quickly progresses towards a clinical worsening and the association of comorbidities in other mucosal organs. Recent evidence supports the existence of a bronchial counterpart of LAR (local allergic asthma), which highlights the pathophysiological links between the upper and lower airways and reinforces the united airways concept. Importantly, several controlled studies have demonstrated the ability of allergen immunotherapy to control LAR symptoms while the therapy is being administered. This review emphasizes the need to implement the NAC in the clinical practice in order to facilitate the recognition of LAR patients, allowing for an early prescription of specific therapies with disease-modifying potential.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available